Prestige BioPharma Limited (KRX:950210)
South Korea flag South Korea · Delayed Price · Currency is KRW
11,650
+390 (3.46%)
At close: Feb 6, 2026

Prestige BioPharma Ratios and Metrics

Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Feb '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
140,024176,683103,966113,582137,620396,635
Market Cap Growth
-24.05%69.94%-8.47%-17.47%-65.30%-
Enterprise Value
222,684210,19744,042-6,736-150,494-63,944
Last Close Price
11650.0014700.008650.009450.0011450.0033000.00
PE Ratio
44.407.92-6.47--
Forward PE
-12.0112.0112.0112.01-
PS Ratio
9.7212.33150.88701.81--
PB Ratio
0.280.350.200.210.320.69
P/TBV Ratio
0.380.480.260.280.320.69
EV/Sales Ratio
15.4514.6763.92---
Debt / Equity Ratio
0.250.280.170.210.010.01
Debt / EBITDA Ratio
---9.11--
Asset Turnover
0.020.020.000--
Inventory Turnover
0.941.180.890.01--
Quick Ratio
0.921.051.532.247.2632.70
Current Ratio
1.171.271.722.317.4632.74
Return on Equity (ROE)
-1.07%0.81%-10.38%-0.59%-42.08%-2.07%
Return on Assets (ROA)
-6.58%-5.71%-5.35%0.10%-13.89%-3.01%
Return on Capital Employed (ROCE)
-13.30%-11.50%-11.00%0.20%-26.80%-3.10%
Earnings Yield
11.25%12.62%-31.66%15.47%-153.65%-1.86%
FCF Yield
-53.71%-52.57%-65.49%-95.65%-74.36%-4.13%
Buyback Yield / Dilution
0.20%-0.44%0.22%--16.46%-20.98%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.